Advertisement

CNS Drugs

, Volume 2, Issue 1, pp 7–17 | Cite as

Management of Benzodiazepine Overdose

  • Jonas Höjer
Practical Therapeutics

Summary

Today, benzodiazepines are the drugs most commonly involved in cases of self-poisoning. Fortunately, compared with several other drugs they are relatively safe in overdose, and symptoms of severe poisoning are rarely observed in young adults with pure benzodiazepine overdosage. However, respiratory depression, hypotension and prolonged coma are often seen in other patient groups with benzodiazepine overdosage, such as the elderly, children and patients with chronic pulmonary disease.

Flumazenil, a specific benzodiazepine antagonist, is a valuable and safe diagnostic and therapeutic tool in the short term management of drug poisoning with involvement of benzodiazepines. Its use should therefore be considered in all unconscious patients admitted because of benzodiazepine overdosage.

In self-poisoning, the drugs ingested are frequently a mixture of several compounds and their identity is often unknown. Flumazenil can also be used diagnostically in cases of unclear multiple drug poisoning or coma of unknown aetiology.

During use of flumazenil, consideration should be paid to a few contraindications, including patients with epilepsy who are receiving long term benzodiazepine medication. Moreover, some precautions should be taken during administration, such as individual titration of the dosage to minimise the risk of inducing benzodiazepine withdrawal syndrome or unmasking toxic effects of other concurrently ingested drugs. A normal electrocardiogram recording before the antidote is given will imply a minimal risk of any adverse reactions in cases of combined intake of benzodiazepine and antidepressants. Further, the short half-life of flumazenil necessitates a period of careful supervision after its administration.

Supportive care in a patient with benzodiazepine overdose includes close monitoring, preferably in the drainage position. If hypotension or prolonged eNS depression occurs, intravenous fluids should be administered. Occasionally, gastric lavage and administration of activated charcoal is indicated, but only if the patient is awake and potentially sensitive to benzodiazepines and if a large dose has been ingested within the last 1 to 2 hours.

Keywords

Adis International Limited Zolpidem Flumazenil Flunitrazepam Gastric Lavage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sternbach LH. The discovery of CNS active 1,4-benzodiazepines. In: Costa E, editor. The benzodiazepines: from molecular biology to clinical practice. New York: Raven Press, 1983: 1–6Google Scholar
  2. 2.
    Greenblatt DJ, Allen MD, Noel BJ, et al. Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther 1977; 21: 497–514PubMedGoogle Scholar
  3. 3.
    Matthew H, Roscoe P, Wright N. Acute poisoning. A comparison of hypnotic drugs. Practitioner 1972; 208: 254–8PubMedGoogle Scholar
  4. 4.
    Divoll M, Greenblatt DJ, Lacasse Y, et al. Benzodiazepine overdosage: plasma concentrations and clinical outcome. Psychopharmacology 1981; 73: 381–3PubMedCrossRefGoogle Scholar
  5. 5.
    Kop P, Cosic V, Simic B, et al. Analysis of the clinical experience in 100 cases of acute intoxication with Apaurin (diazepam). Bull Med Leg Toxicol 1972; 15: 243–51Google Scholar
  6. 6.
    Chapallez S. Intoxications aigues par le nitrazepam (Mogadon). Schweiz Apotheker Ztg 1973; 111: 95–9Google Scholar
  7. 7.
    Castleden CM, George CF, Marcer D, et al. Increased sensitivity to nitrazepam in old age. BMJ 1977; 1: 10–2PubMedCrossRefGoogle Scholar
  8. 8.
    Greenblatt DJ, Allen MD, Shader RI. Toxicity of high dose flurazepam in the elderly. Clin Pharmacol Ther 1977; 21: 355–61PubMedGoogle Scholar
  9. 9.
    Berger R, Green B, Melnick A. Cardiac arrest caused by oral diazepam intoxication. Clin Pediatr 1975; 14: 842–4CrossRefGoogle Scholar
  10. 10.
    Jager U, Hruby K, Haubenstock A, et al. Comparative clinical toxicology of 5 benzodiazepine derivatives. Nervenarzt 1984; 55: 150–3PubMedGoogle Scholar
  11. 11.
    Clark TJH, Collins JV, Tong D. Respiratory depression caused by nitrazepam in patients with respiratory failure. Lancet 1971; 2: 737–8PubMedCrossRefGoogle Scholar
  12. 12.
    Model DG. Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis. Lancet 1974; 2: 869–70PubMedCrossRefGoogle Scholar
  13. 13.
    Finkle BS, McCloskey KL, Goodman LS. Diazepam and drug-associated deaths. A survey in the United States and Canada. JAMA 1979; 242: 429–34PubMedCrossRefGoogle Scholar
  14. 14.
    Martin CD, Chan SC. Distribution of temazepam in body fluids and tissues in lethal overdose. J Anal Toxicol 1986; 10: 77–8PubMedGoogle Scholar
  15. 15.
    Dinovo EC, Gottschalk LA, McGuire FL, et al. Analysis of results of toxicological examinations performed by coroners or medical examiners’ laboratories in 2000 drug-involved deaths in nine major US cities. Clin Chem 1979; 22: 847–50Google Scholar
  16. 16.
    Höjer J, Baehrendtz S, Gustafsson LL. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med 1989; 226: 117–22PubMedCrossRefGoogle Scholar
  17. 17.
    Heyndrickx B. Fatal intoxication due to flunitrazepam [letter]. J Anal Toxicol 1987; 11: 278PubMedGoogle Scholar
  18. 18.
    Mignee C, Garnier R, Conso F, et al. Acute overdosage with flunitrazepam. Therapie 1988; 35: 581–9Google Scholar
  19. 19.
    Sunter JP, Bal TS, Cowan WK. Three cases of fatal triazolam poisoning. BMJ 1988; 297: 719PubMedCrossRefGoogle Scholar
  20. 20.
    Olson KR, Yin L, Osterloh J, et al. Coma caused by trivial triazolam overdose. Am J Emerg Med 1985; 3: 210–1PubMedCrossRefGoogle Scholar
  21. 21.
    Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous depression. Clin Pharmacol Ther 1978; 23: 371–4PubMedGoogle Scholar
  22. 22.
    Hardwicke C, Holt L, James R, et al. Trends in self-poisoning with drugs in Newcastle, New South Wales, 1980-1982. Med J Aust 1986; 144: 453–5PubMedGoogle Scholar
  23. 23.
    Leykin Y, Halpern P, Silbiger A, et al. Acute poisoning treated in the intensive care unit: a case series. Isr J Med Sci 1989; 25: 98–102PubMedGoogle Scholar
  24. 24.
    Proudfoot AT, Par J. Changing pattern of drugs used for self-poisoning. BMJ 1978; 1: 90–3PubMedCrossRefGoogle Scholar
  25. 25.
    Willox DGA. Self-poisoning. A review of patients seen in the Victoria Infirmary, Glasgow. Scott Med J 1985; 30: 220–4PubMedGoogle Scholar
  26. 26.
    Haefely W, Kulcsar A, Mohler H, et al. Possible involvement of GABA in the central actions of benzodiazepines. In: Costa E, Greengard P, editors. Mechanism of action of benzodiazepines. New York: Raven Press, 1975: 131–51Google Scholar
  27. 27.
    Möhler H, Okada T. Benzodiazepine receptor: demonstration in the central nervous system. Science 1977; 198: 849–51PubMedCrossRefGoogle Scholar
  28. 28.
    Hunkeler W, Mohler H, Pieri L, et al. Selective antagonists of benzodiazepines. Nature 1981; 290: 514–6PubMedCrossRefGoogle Scholar
  29. 29.
    Haefely W. Structure and function of the benzodiazepine receptor. CHIMIA 1987; 41: 389–96Google Scholar
  30. 30.
    Caldwell CB, Gross JB. Physostigmine reversal of midazolam induced sedation. Anesthesiology 1982; 57: 125–7PubMedCrossRefGoogle Scholar
  31. 31.
    Meyer BH, Weis OF, Muller FO. Antagonism of diazepam by aminophylline in healthy volunteers. Anesth Analg 1984; 63: 900–2PubMedCrossRefGoogle Scholar
  32. 32.
    Jordan C, Lehane JR, Jones JG. Respiratory depression following diazepam: reversal with high dose naloxone. Anesthesiology 1980; 53: 293–8PubMedCrossRefGoogle Scholar
  33. 33.
    Garber JG, Ominsky AJ, Orkin FK, et al. Physostigmine atropine solution fails to reverse diazepam sedation. Anesth Analg 1980; 54: 58–60Google Scholar
  34. 34.
    Christensen KN, Huttel M. Naloxone does not antagonize diazepam-induced sedation [letter]. Anesthesiology 1979; 51: 187PubMedCrossRefGoogle Scholar
  35. 35.
    Brogden RN, Goa KL. Flumazenil: a reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991; 42: 1061–89PubMedCrossRefGoogle Scholar
  36. 36.
    Darragh A, Lambe R, Kenny M, et al. Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788. Eur J Clin Pharmacol 1983; 24: 569–70PubMedCrossRefGoogle Scholar
  37. 37.
    Darragh A, Lambe R, Scully M, et al. Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788. Lancet 1981; 2: 8–10PubMedCrossRefGoogle Scholar
  38. 38.
    Darragh A, Lambe R, O’Boyle C, et al. Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788. Psychopharmacology 1983; 80: 192–5PubMedCrossRefGoogle Scholar
  39. 39.
    Scollo-Lavizzari G. The anticonvulsant effect of the benzodiazepine antagonist, Ro 15-1788: an EEG study in 4 cases. Eur Neurol 1984; 23: 1–6PubMedCrossRefGoogle Scholar
  40. 40.
    Klotz U, Ziegler G, Reimann IW. Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. Eur J Clin Pharmacol 1984; 27: 115–7PubMedGoogle Scholar
  41. 41.
    Lauven PM, Schwilden H, Stoeckel H, et al. The effects of a benzodiazepine antagonist Ro 15-1788 in the presence of stable concentrations of midazolam. Anesthesiology 1983; 63: 61–4CrossRefGoogle Scholar
  42. 42.
    Scollo-Lavizzari G. First clinical investigation of the benzodiazepine antagonist Ro 15-1788 in comatose patients. Eur Neurol 1983; 22: 7–11PubMedCrossRefGoogle Scholar
  43. 43.
    Geller E, Niv D, Rudick V, et al. The use of Ro 15-1788: a benzodiazepine antagonist in the diagnosis and treatment of benzodiazepine overdose [abstract]. Anesthesiology 1984; 61: A135CrossRefGoogle Scholar
  44. 44.
    Hofer P, Scollo-Lavizzari G. Benzodiazepine antagonist Ro 15-1788 in self-poisoning. Diagnostic and therapeutic use. Arch Intern Med 1985; 145: 663–4PubMedCrossRefGoogle Scholar
  45. 45.
    Höjer J, Baehrendtz S, Matell G, et al. Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study. BMJ 1990; 301: 1308–11PubMedCrossRefGoogle Scholar
  46. 46.
    Höjer J, Baehrendtz S. The effect of flumazenil (Ro 15-1788) in the management of self-induced benzodiazepine poisoning. Acta Med Scand 1988; 224: 357–65PubMedCrossRefGoogle Scholar
  47. 47.
    O’Sullivan GF, Wade DN. Flumazenil in the management of acute drug overdosage with benzodiazepines and other agents. Clin Pharmacol Ther 1987; 42: 254–9PubMedCrossRefGoogle Scholar
  48. 48.
    Ritz R, Zuber M, Elsasser S, et al. Use of flumazenil in intoxicated patients with coma. A double-blind placebo-controlled study in ICU. Intensive Care Med 1990; 16: 242–7PubMedCrossRefGoogle Scholar
  49. 49.
    Amrein R, Leishman B, Bentzinger C, et al. Flumazenil in benzodiazepine antagonism: actions and clinical use in intoxications and anaesthesiology. Med Toxicol 1987; 2: 411–29Google Scholar
  50. 50.
    Naef MM, Forster A, Nahory A, et al. Flumazenil antagonizes the sedative action of Zolpidem. A new imidazopyridine hypnotic [abstract]. Anesthesiology 1989; 71: A298CrossRefGoogle Scholar
  51. 51.
    Lheureux P, Debailleul G, De Witte O, et al. Zolpidem intoxication mimicking narcotic overdose: response to flumazenil. Hum Exp Toxicol 1990; 9: 105–7PubMedCrossRefGoogle Scholar
  52. 52.
    Lheureux P, Vranckx M, Askenasi R. Use and misuse of flumazenil in clinical toxicology. In: Vincent JL, editor. Update in intensive care and emergency medicine. Berlin Heidelberg: Springer Verlag, 1991: 482–90Google Scholar
  53. 53.
    Klotz U, Zielger G, Rosenkranz B, et al. Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol? Br J Clin Pharmacol 1986; 22: 513–20PubMedCrossRefGoogle Scholar
  54. 54.
    Scollo-Lavizzari G, Matthis H. Benzodiazepine antagonist (Ro 15-1788) in ethanol intoxication: a pilot study. Eur Neurol 1985; 24: 352–4PubMedCrossRefGoogle Scholar
  55. 55.
    Ziegler WH, Fliickiger A, Meier PJ, et al. Effects of the benzodiazepine-antagonist flumazenil (Anexate) in acute ethanol intoxication. Therapie 1988; 43: 143–63Google Scholar
  56. 56.
    Clausen TG, Wolff J, Carl P, et al. The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man. Eur J Clin Pharmacol 1990; 38: 233–6PubMedCrossRefGoogle Scholar
  57. 57.
    Bodenham A, Brownlie G, Dixon JS, et al. Reversal of sedation by prolonged infusion of flumazenil (Anexate, Ro 15-1788). Anaesthesia 1988; 43: 376–8PubMedCrossRefGoogle Scholar
  58. 58.
    Pollard BJ, Masters AP, Bunting P. The use of flumazenil (Anexate, Ro 15-1788) in the management of drug overdose. Anaesthesia 1989; 44: 137–8PubMedCrossRefGoogle Scholar
  59. 59.
    Roald OK, Dahl V. Flunitrazepam intoxication in a child successfully treated with the benzodiazepine antagonist flumazenil. Crit Care Med 1989; 17: 1355–6PubMedGoogle Scholar
  60. 60.
    Geller E, Niv D, Weinbrum A, et al. The use of flumazenil in the treatment of 34 intoxicated patients. Resuscitation 1988; Suppl. 16: 57–62CrossRefGoogle Scholar
  61. 61.
    Höjer J, Baehrendtz S, Magnusson A, et al. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. Acta Anaesthesiol Scand 1991; 35: 584–90PubMedCrossRefGoogle Scholar
  62. 62.
    Winkler E, Almog S, Kriger D, et al. Use of flumazenil in the diagnosis and treatment of patients with coma of unknown etiology. Crit Care Med 1993; 21: 538–42PubMedCrossRefGoogle Scholar
  63. 63.
    Skeie B, Emhjellen S, Wickstrom E, et al. Antagonism of flunitrazepam-induced sedative effects by flumazenil in patients after surgery under general anaesthesia. A double-blind placebo-controlled investigation of efficacy and safety. Acta Anaesthesiol Scand 1988; 32: 290–4Google Scholar
  64. 64.
    Burr W, Sandham P, Judd A. Death after flumazenil [letter]. BMJ 1989; 298: 1713PubMedCrossRefGoogle Scholar
  65. 65.
    Bodenham AR. Death after flumazenil [letter]. BMJ 1989; 299: 457PubMedCrossRefGoogle Scholar
  66. 66.
    Savic I, Widén L, Stone-Elander S. Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 1991; 337: 133–7PubMedCrossRefGoogle Scholar
  67. 67.
    Short TG, Maling T, Galletly DC. Ventricular arrhythmia precipitated by flumazenil. BMJ 1988; 296: 1070–1PubMedCrossRefGoogle Scholar
  68. 68.
    Marchant B, Wray R, Leach A, et al. Flumazenil causing convulsions and ventricular tachycardia [letter]. BMJ 1989; 299: 860PubMedCrossRefGoogle Scholar
  69. 69.
    Aarseth HP, Bredesen JE, Grynne B, et al. Benzodiazepine-receptor antagonist, a clinical double blind study. J Toxicol Clin Toxicol 1988; 26: 283–92PubMedGoogle Scholar
  70. 70.
    Knudsen L, Lonka L, Sorensen BH, et al. Benzodiazepine intoxication treated with flumazenil (Anexate, Ro 15-1788). Anaesthesia 1988; 43: 274–6PubMedCrossRefGoogle Scholar
  71. 71.
    Levy DE, Bates D, Caronna JJ, et al. Prognosis in nontraumatic coma. Ann Int Med 1981; 94: 293–301PubMedGoogle Scholar
  72. 72.
    Plum F, Posner JB, editors. Approach to the unconscious patient. In: The diagnosis of stupor and coma. Philadelphia: FA Davis Co, 1980: 345–64Google Scholar
  73. 73.
    Rubenstein E. Intoxication by centrally acting agents. In: Rubenstein E, Federman DD, editors. Scientific American medicine. New York: Scientific American 1989; 8(I): 2–13Google Scholar
  74. 74.
    Mora CT, Torjman M, White PF. Effects of diazepam and flumazenil on sedation and hypoxic ventilatory response. Anesth Analg 1989; 68: 473–8PubMedCrossRefGoogle Scholar
  75. 75.
    Sioufi A, Dubois JP. Review: chromatography of benzodiazepines. J Chromatogr 1990; 531: 459–80PubMedCrossRefGoogle Scholar
  76. 76.
    Lillsunde P, Seppälä T. Simultaneous screening and quantitative analysis of benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection. J Chromatogr 1990; 533: 97–110PubMedCrossRefGoogle Scholar
  77. 77.
    Riou B, Barriot P, Rimailhoa A, et al. Treatment of severe chloroquine poisoning. N Engl J Med 1988; 318: 1–6PubMedCrossRefGoogle Scholar
  78. 78.
    Boehnert MT, Lovejoy Jr FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313: 474–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Jonas Höjer
    • 1
  1. 1.Department of Internal MedicineSouthern Hospital, Karolinska InstituteStockholmSweden

Personalised recommendations